Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Employees

2,498

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
26-03-06	91.20 $	-1.49%	1,272,484
26-03-05	92.58 $	-0.47%	1,538,279
26-03-04	93.02 $	-0.30%	1,070,795
26-03-03	93.30 $	+1.16%	2,133,437
26-03-02	92.23 $	-1.78%	1,886,662

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

91.20USD

Average target price

132.57USD

Spread / Average Target

+45.36%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
91.20 ^USD	-1.49%		-2.88%	-10.71%

Mar. 05	Guardant Health Insider Sold Shares Worth $3,812,661, According to a Recent SEC Filing	MT
Mar. 04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI

Capitalization	11.96B 10.31B 9.31B 8.93B 16.29B 1,099B 17.05B 110B 44.1B 527B 44.9B 43.94B 1,886B	P/E ratio 2026 *	-31x	P/E ratio 2027 *	-43.1x
Enterprise value	12.37B 10.67B 9.63B 9.24B 16.85B 1,137B 17.64B 114B 45.61B 545B 46.44B 45.45B 1,950B	EV / Sales 2026 *	9.73x	EV / Sales 2027 *	7.62x
Free-Float	95.44%	Yield 2026 *	-	Yield 2027 *	-

Mar. 05	Guardant Health Insider Sold Shares Worth $3,812,661, According to a Recent SEC Filing	MT
Mar. 04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI
Feb. 19	Guardant Health, Inc., Q4 2025 Earnings Call, Feb 19, 2026
Feb. 19	(GH) Guardant Health Expects Full Year 2026 Revenue Range $1.25B - $1.28B, vs. FactSet Est of $1.25B	MT
Feb. 19	Guardant Health Q4 Adjusted Loss Narrows, Revenue Rises; 2026 Revenue Guidance Set	MT
Feb. 19	Earnings Flash (GH) Guardant Health, Inc. Reports Q4 Revenue $281.3M, vs. FactSet Est of $272.4M	MT
Feb. 19	Earnings Flash (GH) Guardant Health, Inc. Posts Q4 Adjusted Loss $0.50 per Share, vs. FactSet Est of $-0.77	MT
Feb. 19	Guardant Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 19	Guardant Health, Inc. Provides Revenue Guidance for the Fiscal Year 2026	CI
Feb. 18	Guardant Health, Inc. (NasdaqGS:GH) acquired Metasight Diagnostics for approximately $150 million.	CI
Feb. 17	Baird Initiates Guardant Health at Outperform With $120 Price Target	MT
Feb. 02	Guardant Health, Inc. Announces Publication of the Largest Study to Date Evaluating Circulating Tumors forMRD Detection in Patients with Rescted Stage III Colon Cancer After Surgery and Before Adjuvant Chemotherapy	CI
Jan. 30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT

Feb. 17	Baird Initiates Guardant Health at Outperform With $120 Price Target	MT
Jan. 30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT
Dec. 02	Morgan Stanley Raises Price Target on Guardant Health to $130 From $105, Keeps Overweight Rating	MT
25-10-30	UBS Adjusts Guardant Health Price Target to $110 From $80, Maintains Buy Rating	MT
25-09-29	Guardant Health Says US FDA Approves its Blood Test as Companion Diagnostic for Eli Lilly's Inluriyo	MT

Guardant Health, Inc. Stock

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Valuation: Guardant Health, Inc.

Chart: Guardant Health, Inc.

Latest news: Guardant Health, Inc.

Last Transcript: Guardant Health, Inc.

Analysts' recommendations: Guardant Health, Inc.

Press Releases: Guardant Health, Inc.

News in other languages: Guardant Health, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Guardant Health, Inc.

ETFs: Guardant Health, Inc.

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Mar. 04	Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America	BU
Mar. 03	Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened	BU
Feb. 27	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
Feb. 19	Guardant Health: Q4 Earnings Snapshot	AQ
Feb. 19	Guardant Health : Q4 and Full Year 2025 Earnings Call	PU

Dec. 11	Guardant Health et le Policlinico Gemelli lancent un service interne de tests de biopsie liquide en Italie
Dec. 11	Guardant Health und Policlinico Gemelli starten internen Flüssigbiopsie-Testdienst in Italien
25-10-16	Guardant Health et ses collaborateurs présenteront de nouvelles données sur le continuum des soins contre le cancer lors du congrès ESMO 2025
25-10-16	Guardant Health und Kooperationspartner präsentieren auf der ESMO 2025 neue Daten zur gesamten Krebsbehandlungskette
25-07-30	Guardant Health und James Van Der Beek schließen sich zusammen, um das Bewusstsein für neue Fortschritte bei der Darmkrebsvorsorge für Erwachsene ab 45 Jahren zu schärfen

1 day	-1.49%
1 week	-2.88%
Current month	-2.88%
1 month	-10.46%
3 months	-12.45%
6 months	+51.58%
Current year	-10.71%

1 week	88.21	96.52
1 month	88.21	113.78
Current year	88.21	120.74
1 year	34.88	120.74
3 years	15.81	120.74
5 years	15.81	169.42
10 years	15.81	181.07

Manager	Title	Age	Since
AmirAli Talasaz CEO	Chief Executive Officer	46	2021-08-04
Helmy Eltoukhy CEO	Chief Executive Officer	47	2012-12-31
Michael Bell DFI	Director of Finance/CFO	57	2021-01-04

Director	Title	Age	Since
Helmy Eltoukhy CHM	Chairman	47	2021-08-04
AmirAli Talasaz CHM	Chairman	46	2012-12-31
Ian Clark BRD	Director/Board Member	64	2016-11-30

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GUARDANT HEALTH, INC.	-1.49%	-2.88%	+131.94%	+215.79%	11.96B
BIOMÉRIEUX	-0.73%	-6.19%	-19.43%	-2.26%	13.06B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+4.83%	+4.11%	-9.89%	-5.27%	6.21B
CARIS LIFE SCIENCES, INC.	-3.28%	-7.70%	-	-	5.25B
LANTHEUS HOLDINGS, INC.	-4.91%	-3.14%	-31.77%	-3.56%	4.69B
DIASORIN S.P.A.	+0.06%	-2.82%	-31.66%	-38.18%	4.31B
ANDON HEALTH CO., LTD.	-2.45%	+10.48%	+16.35%	+1.47%	2.99B
AUTOBIO DIAGNOSTICS CO., LTD.	+1.74%	-3.61%	-16.55%	-42.51%	2.9B
10X GENOMICS, INC.	-3.84%	-9.72%	+77.86%	-57.52%	2.66B
VCANBIO CELL & GENE ENGINEERING CORP., LTD	+10.00%	+12.69%	+35.82%	+72.05%	2.04B
Average	-0.01%	-1.31%	+16.97%	+15.56%	5.61B
Weighted average by Cap.	-0.52%	-2.16%	+24.77%	+43.55%

	2026 *	2027 *
Net sales	1.27B 1.1B 990M 950M 1.73B 117B 1.81B 11.7B 4.69B 56.06B 4.77B 4.67B 200B	1.64B 1.41B 1.27B 1.22B 2.23B 150B 2.33B 15.05B 6.03B 72.09B 6.14B 6.01B 258B
Net income	-380M -327M -296M -284M -517M -34.91B -541M -3.49B -1.4B -16.74B -1.43B -1.4B -59.87B	-266M -229M -207M -199M -362M -24.46B -379M -2.45B -981M -11.73B -999M -977M -41.94B
Net Debt	411M 354M 320M 307M 560M 37.78B 586M 3.78B 1.52B 18.12B 1.54B 1.51B 64.79B	509M 439M 396M 380M 693M 46.8B 726M 4.69B 1.88B 22.44B 1.91B 1.87B 80.26B